- ROUNDTABLE: Improving patient outcomes, controlling costs with OTCs
- State of the market: Are generic drugs approaching their peak?
- Teva launches authorized generic version of Pfizer's Detrol LA
- Reports: Three drug makers have sights on Pfizer's generics unit
- Lipitor may be the first statin to switch to OTC
NEW YORK — Pfizer has cleared one of the main legal hurdles in its effort to purchase drug maker King Pharmaceuticals, Pfizer said Friday.
Pfizer, the world’s largest drug company, said the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 had been terminated, one of the conditions necessary for the completion of Pfizer’s tender offer for King.
Pfizer announced plans in October to purchase Bristol, Tenn.-based King for $3.6 billion, or $14.25 per share.